Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

Inclusion Criteria: * Have histologically confirmed endometrial carcinoma, cervical carcinoma or uterine sarcoma, refractory or persistent to chemotherapy or recurrent disease after at least one line of chemotherapy. * Presence of an index lesion amenable to hypofractionated stereotactic radiotherapy * At least one lesion outside the radiation field that can be followed by imaging for clinical response according to RECIST and irRC * Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion before and after radiotherapy if technically feasible. * Have a performance status of 0 or 1 or 2 on the ECOG Performance Scale. * Demonstrate adequate organ function Exclusion Criteria: * Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. * Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 agent * Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to the first dose of trial treatment, * Known history of active TB (Bacillus Tuberculosis), Human Immunodeficiency Virus (HIV), HTLV or syphilis,non-infectious pneumonitis, has active autoimmune disease. * Has active central nervous system metastases and/or carcinomatous meningitis